Get started
Clearside Biomedical, Inc.Clearside Biomedical, Inc.Clearside Biomedical, Inc.

Clearside Biomedical, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CLSD chart


Full chart

CLSD upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪85.21 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.50 USD
Net income (FY)
‪−32.48 M‬ USD
Revenue (FY)
‪8.23 M‬ USD
Shares float
‪63.23 M‬
Beta (1Y)
0.97

Employees


Employees (FY)
30
Change (1Y)
−6 −16.67%
Revenue / Employee (1Y)
‪274.20 K‬ USD
Net income / Employee (1Y)
‪−1.08 M‬ USD

About Clearside Biomedical, Inc.


Sector
Health Technology
CEO
George M. Lasezkay
Headquarters
Alpharetta
Website
clearsidebio.com
Founded
2011
FIGI
BBG002D4D4X3
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CLSD news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CLSD is 1.14 USD — it has increased by 2.70% in the past 24 hours. Watch Clearside Biomedical, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Clearside Biomedical, Inc. stocks are traded under the ticker CLSD.
CLSD stock has risen by 14.14% compared to the previous week, the month change is a −30.70% fall, over the last year Clearside Biomedical, Inc. has showed a 31.03% increase.
We've gathered analysts' opinions on Clearside Biomedical, Inc. future price: according to them, CLSD price has a max estimate of 8.00 USD and a min estimate of 5.00 USD. Watch CLSD chart and read a more detailed Clearside Biomedical, Inc. stock forecast: see what analysts think of Clearside Biomedical, Inc. and suggest that you do with its stocks.
CLSD reached its all-time high on Oct 10, 2016 with the price of 25.08 USD, and its all-time low was 0.56 USD and was reached on Aug 28, 2019. View more price dynamics on CLSD chart.
See other stocks reaching their highest and lowest prices.
CLSD stock is 4.50% volatile and has beta coefficient of 0.97. Track Clearside Biomedical, Inc. stock price on the chart and check out the list of the most volatile stocks — is Clearside Biomedical, Inc. there?
Today Clearside Biomedical, Inc. has the market capitalization of ‪85.21 M‬, it has decreased by −5.45% over the last week.
Yes, you can track Clearside Biomedical, Inc. financials in yearly and quarterly reports right on TradingView.
Clearside Biomedical, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
CLSD earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.14 USD resulting in a 26.29% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about Clearside Biomedical, Inc. earnings.
Clearside Biomedical, Inc. revenue for the last quarter amounts to ‪90.00 K‬ USD, despite the estimated figure of ‪126.50 K‬ USD. In the next quarter, revenue is expected to reach ‪130.00 K‬ USD.
CLSD net income for the last quarter is ‪−7.59 M‬ USD, while the quarter before that showed ‪−11.76 M‬ USD of net income which accounts for 35.44% change. Track more Clearside Biomedical, Inc. financial stats to get the full picture.
No, CLSD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 30.00 employees. See our rating of the largest employees — is Clearside Biomedical, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Clearside Biomedical, Inc. EBITDA is ‪−25.66 M‬ USD, and current EBITDA margin is −301.20%. See more stats in Clearside Biomedical, Inc. financial statements.
Like other stocks, CLSD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Clearside Biomedical, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Clearside Biomedical, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Clearside Biomedical, Inc. stock shows the sell signal. See more of Clearside Biomedical, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.